What Is Hsp110? Biological Background and Function

Hsp110 (Heat Shock Protein 110) is a member of the HSP110/SSE subfamily, which belongs to the broader HSP70 superfamily. Encoded by the HSPH1 gene in humans, Hsp110 is one of the largest cytosolic heat shock proteins, with an apparent molecular weight of approximately 105–110 kDa. Despite sharing structural homology with canonical Hsp70 proteins, Hsp110 exhibits distinct biochemical properties, including a greatly reduced ATPase activity and an extended acidic loop insertion within its substrate-binding domain.

The primary biological role of Hsp110 is to act as a molecular chaperone that prevents the irreversible aggregation of misfolded or denatured proteins under stress conditions such as heat shock, oxidative stress, and hypoxia. In addition to its holdase chaperone activity, Hsp110 serves as a highly efficient nucleotide exchange factor (NEF) for Hsp70, catalyzing the release of ADP from Hsp70 and thereby regulating the Hsp70 chaperone cycle. This functional partnership between Hsp110 and Hsp70 is critical for the refolding of stress-denatured proteins and for the maintenance of cellular protein homeostasis.

Hsp110 is constitutively expressed in most mammalian tissues and is further induced by proteotoxic stress, making it an important component of the cell's protein quality control machinery.

Structural Features of Hsp110

Structurally, Hsp110 shares the two-domain architecture of Hsp70 proteins, comprising an N-terminal nucleotide-binding domain (NBD) and a C-terminal substrate-binding domain (SBD). However, several key structural differences distinguish Hsp110 from classical Hsp70 members:

• Extended acidic loop: Hsp110 contains a unique acidic insertion within its SBD that is absent in Hsp70. This loop is thought to reduce the affinity of Hsp110 for unfolded polypeptide substrates, consistent with its primary holdase rather than foldase activity.
• Reduced intrinsic ATPase activity: Unlike Hsp70, Hsp110 has very low intrinsic ATPase activity, meaning it does not independently drive a robust chaperone folding cycle.
• Interdomain communication: The allosteric communication between the NBD and SBD in Hsp110 differs from that in Hsp70, which underlies the distinct functional roles of these two chaperone families.

These structural features collectively explain why Hsp110 functions more effectively as a substrate holder and NEF rather than an autonomous foldase, and why its cooperation with Hsp70 and Hsp40 co-chaperones is essential for efficient protein disaggregation and refolding in mammalian cells.

Research Applications of Recombinant Human Hsp110 Protein

Recombinant Human Hsp110 Protein is a versatile tool for a wide range of biochemical and cell biological research applications. Key areas include:

• In vitro chaperone activity assays: Recombinant Hsp110 is used to study holdase and disaggregation activities using model substrates such as luciferase or citrate synthase. These assays help characterize the chaperone mechanism and identify modulators of its activity.
• Hsp70 chaperone cycle studies: As a NEF for Hsp70, recombinant Hsp110 is used in reconstituted chaperone systems to dissect the biochemical steps of Hsp70-assisted protein folding and disaggregation.
• Cancer biology research: Hsp110 is overexpressed in several cancers, including colorectal, gastric, and breast cancers. Recombinant protein supports studies on Hsp110's role in tumor cell survival, drug resistance, and as a potential therapeutic target.
• Neurodegeneration models: Given Hsp110's role in suppressing protein aggregation, it is used in research on amyloid-related diseases and polyglutamine disorders, where aggregation-prone proteins must be managed by the chaperone network.
• Protein interaction studies: Recombinant Hsp110 is suitable for co-immunoprecipitation, pull-down assays, and surface plasmon resonance experiments to map interactions with Hsp70, Hsp40, and client proteins.
• Immunological research: Hsp110 has been explored as a carrier for tumor antigens in cancer vaccine development, leveraging its ability to form stable complexes with antigenic peptides.

Handling, Storage, and Reconstitution Guidelines

Proper handling of Recombinant Human Hsp110 Protein is essential to preserve its biological activity and structural integrity. Researchers should follow general best-practice guidelines for recombinant proteins:

• Storage: Upon receipt, aliquot the protein to avoid repeated freeze-thaw cycles, which can lead to aggregation and loss of chaperone activity. Store aliquots at –80 °C for long-term preservation.
• Reconstitution: If supplied in lyophilized form, reconstitute in the manufacturer's recommended buffer (typically a physiological buffer such as PBS with a carrier protein such as BSA at 0.1% to enhance stability). Allow the protein to dissolve gently without vortexing.
• Working concentrations: Optimal concentrations depend on the assay format. For in vitro chaperone assays, titration experiments are recommended to determine the appropriate molar ratio relative to substrate proteins.
• Avoid detergents: Hsp110 is sensitive to denaturing conditions; avoid SDS or other denaturing detergents in working buffers when activity is required.
• Quality assessment: Verify protein integrity and purity by SDS-PAGE and confirm biological activity using a validated holdase or NEF assay before use in critical experiments.

Always consult the specific product datasheet for lot-specific concentration, purity, and activity information.

Hsp110 in Disease and Translational Research

Beyond its fundamental role in protein homeostasis, Hsp110 has emerged as a clinically relevant protein with implications across multiple disease areas:

Cancer: Hsp110 is overexpressed in colorectal cancer, gastric cancer, and other malignancies. Its expression has been associated with tumor cell proliferation, resistance to apoptosis, and poor prognosis. Notably, mutations affecting Hsp110 splicing have been identified in microsatellite-unstable colorectal cancers, suggesting a tumor-suppressive role in certain contexts. These findings make Hsp110 an attractive biomarker candidate and potential drug target.

Neurodegeneration: In models of Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS), Hsp110 cooperates with Hsp70 and Hsp40 to suppress the aggregation of disease-causing proteins such as alpha-synuclein and mutant huntingtin. Recombinant Hsp110 is therefore used to study therapeutic chaperone strategies.

Immunology and vaccine development: Hsp110 can form non-covalent complexes with antigenic peptides and stimulate antigen-specific immune responses when administered in vivo. This immunogenic property has been exploited in preclinical cancer vaccine platforms, where Hsp110-antigen fusion proteins or complexes are used to elicit cytotoxic T-lymphocyte responses against tumor antigens.

Cardiac and ischemic stress: Hsp110 expression is induced by ischemic preconditioning and has been shown to confer cytoprotective effects in cardiac cells, highlighting potential roles in cardioprotection research.